Literature DB >> 24002080

Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.

Marco Armbruster1, Steven Sourbron, Alexander Haug, Christoph J Zech, Michael Ingrisch, Christoph J Auernhammer, Konstantin Nikolaou, Philipp M Paprottka, Carsten Rist, Maximilian F Reiser, Wieland H Sommer.   

Abstract

OBJECTIVES: The objective of this study was to evaluate the correlation between dynamic gadoxetic acid-enhanced magnetic resonance imaging parameters and specific uptake values (SUVs) derived from ¹⁸fluorodeoxyglucose (¹⁸F-FDG) and ⁶⁸Ga-DOTA-Tyr(3)-octreotate (⁶⁸Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT) in patients with liver metastases of neuroendocrine neoplasms.
METHODS: A total of 42 patients with hepatic metastases of neuroendocrine neoplasms were prospectively enrolled and underwent both dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and PET/CT, using either ¹⁸F-FDG or ⁶⁸Ga-DOTATATE as tracer. The DCE-MRI was performed at 3 T with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid acquiring 48 slices every 2.2 seconds for 5 minutes. Three regions of interest (ROIs) representing the liver background and up to 3 ROIs representing metastatic liver tissue were coregistered in the PET/CT and in the DCE-MRI data sets. For each patient, a dedicated dual-inlet, 2-compartment uptake model was fitted to the enhancement curves of DCE-MRI ROIs and perfusion parameters were calculated. Lesion-to-background ratios of SUVs were correlated with corresponding lesion-to-background ratios of the perfusion parameters arterial plasma flow, venous plasma flow, total plasma flow, extracellular mean transit time, extracellular volume, arterial flow fraction, intracellular uptake rate, and hepatic uptake fraction using the Spearman coefficient.
RESULTS: Whereas the lesion-to-background ratios of arterial plasma flow and arterial flow fraction of liver metastases correlated negatively with the lesion-to-background ratios of SUV(mean) derived from ⁶⁸Ga-DOTATATE PET/CT (r = -0.54, P < 0.001; r = -0.39, P < 0.001, respectively), they correlated positively with the lesion-to-background ratios of SUV(mean) derived from ¹⁸F-FDG-PET/CT (r = 0.51, P < 0.05; r = 0.68, P < 0.01, respectively). The lesion-to-background ratios of the DCE-MRI parameters extracellular mean transit time and extracellular volume correlated very weakly with the lesion-to-background ratios of SUV(mean) from ⁶⁸Ga-DOTATATE PET/CT, whereas venous plasma flow, total plasma flow, hepatic uptake fraction, and intracellular uptake rate showed no correlation between DCE-MRI and PET/CT.
CONCLUSIONS: Both ⁶⁸Ga-DOTATATE and ¹⁸fluorodeoxyglucose PET/CT partially correlate with MRI perfusion parameters from the dual-inlet, 2-compartment uptake model. The results indicate that the paired imaging methods deliver complementary functional information.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24002080     DOI: 10.1097/RLI.0b013e3182a4eb4a

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  11 in total

1.  Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

Authors:  Christopher Klenk; Rakhee Gawande; Vy Thao Tran; Jennifer Trinh Leung; Kevin Chi; Daniel Owen; Sandra Luna-Fineman; Kathleen M Sakamoto; Alex McMillan; Andy Quon; Heike E Daldrup-Link
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

2.  MR imaging of primary hepatic neuroendocrine neoplasm and metastatic hepatic neuroendocrine neoplasm: a comparative study.

Authors:  RuoFan Sheng; YanHong Xie; MengSu Zeng; Yuan Ji; ShengXiang Rao; CaiZhong Chen
Journal:  Radiol Med       Date:  2015-04-24       Impact factor: 3.469

Review 3.  The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.

Authors:  Alireza Mojtahedi; Sanjay Thamake; Izabela Tworowska; David Ranganathan; Ebrahim S Delpassand
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

Review 4.  Prognostication and response assessment in liver and pancreatic tumors: The new imaging.

Authors:  Riccardo De Robertis; Paolo Tinazzi Martini; Emanuele Demozzi; Gino Puntel; Silvia Ortolani; Sara Cingarlini; Andrea Ruzzenente; Alfredo Guglielmi; Giampaolo Tortora; Claudio Bassi; Paolo Pederzoli; Mirko D'Onofrio
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

5.  68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis?

Authors:  Terence Jackson; Muhammad Darwish; Edward Cho; Kei Nagatomo; Houssam Osman; D Rohan Jeyarajah
Journal:  Abdom Radiol (NY)       Date:  2021-03-04

6.  Use of 68Ga DOTATATE, a new molecular imaging agent, for neuroendocrine tumors.

Authors:  Raymond Andrew LeBlanc; Umesh D Oza; Ryan Hayden; Hanna Fanous
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-11-04

7.  PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype?

Authors:  Ali Pirasteh; Christopher Riedl; Marius Erik Mayerhoefer; Romina Grazia Giancipoli; Steven Mark Larson; Lisa Bodei
Journal:  Clin Transl Imaging       Date:  2019-09-20

8.  Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma.

Authors:  Yong Cui; Zhong-Wu Li; Xiao-Ting Li; Shun-Yu Gao; Ying Li; Jie Li; Hui-Ci Zhu; Lei Tang; Kun Cao; Ying-Shi Sun
Journal:  Oncotarget       Date:  2017-11-20

9.  Simultaneous evaluation of perfusion and morphology using GRASP MRI in hepatic fibrosis.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Robert Grimm; Steven Sourbron; Hersh Chandarana; Yohan Son; Susmita Basak; Kyoung-Bun Lee; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  Eur Radiol       Date:  2021-06-12       Impact factor: 5.315

10.  The impact of 18F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract.

Authors:  O Barachini; R Bernt; S Mirzaei; C Pirich; K Hergan; S Zandieh
Journal:  BMC Med Imaging       Date:  2020-02-24       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.